{"id":2886,"date":"2012-09-21T19:37:55","date_gmt":"2012-09-21T23:37:55","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=2886"},"modified":"2012-09-22T22:57:48","modified_gmt":"2012-09-23T02:57:48","slug":"traders-find-their-thrill-on-blueberry-hill-cdxc","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/traders-find-their-thrill-on-blueberry-hill-cdxc-2886","title":{"rendered":"Traders Find Their Thrill On Blueberry Hill (CDXC)"},"content":{"rendered":"

According to nutritionists and the medical profession, nothing packs a punch like the blueberry. The little blue package ranks the highest of any fruit for free radical-fighting antioxidants and it is loaded with vitamin C. Native Americans even used the blueberry as a cough remedy. Yesterday afternoon, ChromaDex (OTC:CDXC) released the Phase 2\/3 findings<\/a> for its nutritional ingredient, pTeroPure, derived from a chemical\u00a0known as pterostilbene that is\u00a0found in blueberries. A spokesperson from the University of Mississippi School of Pharmacy reported that patients receiving high doses of the chemical saw an overall reduction in their blood pressure.<\/p>\n

Perhaps traders were either digesting the recent gains in the stock or their breakfast as shares of ChromaDex opened the morning just a penny above yesterday\u2019s closing price of $0.95. The initial transaction of the trading session also marked the high for the day. Any enthusiasm buyers showed for the stock quickly died on the vine.\u00a0Share prices hit bottom for the day when they traded for $0.85 with less than an hour to go in the trading week. The stock ended the day with a loss of 6% to close down 6 cents at $0.89. The number of shares exchanging hands during the session fell just shy of the 650,000 traded on an average day.<\/p>\n

Over the last 12 months, the stock has bounced around like a four-year-old snacking on a fruity-tasting, sugary candy. In January, share prices climbed 150% to $1.20 and the company signed a letter of intent<\/a> with Glanbia Nutritionals for the distribution of pTeroPure in North America. By mid-May, the stock had stair-stepped to a new 52-week low when shares traded at $0.44. Just four days ago, the stock hit a fresh annual high of $1.25. Traders will have the weekend to decide whether the recent pull back in the stock is just a pause that refreshes, or if it marks the beginning of a significant correction.<\/p>\n

Other recent news for Chromadex includes:<\/p>\n